Wockhardt Limited has informed the Exchange regarding a press release dated December 16, 2024, titled "Zaynich (Zidebactam/Cefepime, WCK 5222) enables US cancer patient undergo successful liver transplant and resume chemotherapy by eradicating dual extreme-drug resistant Gram negative pathogens".